glp 1 and cancer treatment GLP-1s appear to cut risk. Researchers are asking why how : NPR Could GLP-1 Drugs Reduce Obesity-Related

They can be, but need extra monitoring

Journal of education and health promotion , 11 , 98

Long-term Neuroprotection: Helps protect against neurodegenerative conditions by maintaining neuron health and function, thereby prolonging cognitive longevity

However, in a sensitivity analysis of the REWIND study with dulaglutide, the relative risk reduction for a 40% or 50% decrease in eGFR was 30% and 44%, both significant, in the dulaglutide group compared to placebo, respectively.92 This lower risk of developing macroalbuminuria was also confirmed in an exploratory analysis of the ELIXA (lixisenatide) study.93 In the EXSCEL study (exenatide LAR), renal episodes were analyzed as additional microvascular episodes, and no differences were observed in the risk of episodes related to decreased eGFR, but differences were observed in the composite episode, which included decreased eGFR and macroalbuminuria, although only after adjustment94 (Table 2)

In May, Novo Nordisk announced that it was pulling all TV ads for the weight-loss drug semaglutide